Our meta-analysis results suggested the PIK3CA gene as a predictor for pCR in TA-treated breast cancer patients with PIK3CA mt (17.1%) and PIK3CAwt (24.7%) [106]. This evidence concerns the gene PIK3CA and breast carcinoma.